[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
In a phase I/II study the tolerable doses and antileukemic efficacy of the combination AMSA and etoposide (VP 16-213) was assessed in 20 patients with refractory acute myeloid leukemia. The following 5 day treatment course was found tolerable and effective: AMSA 210 mg/m2/die on days 2, 3 and 4, and etoposide on days 1 and 5 as a 1 h infusion of 100 mg/m2 followed by a 23-h continuous infusion of 230 mg/m2. In 5 of 20 patients partial remissions were achieved; 4 of these patients were primarily resistant against two TAD induction cycles. Bone marrow aplasia without a residual blast population was achieved in 7 of the 8 patients with primary TAD resistance. AMSA/etoposide thus seems to express an antileukemic efficacy without cross-resistance against TAD.
D000609:Aminoacridines / Q000008:administration & dosage; D000616:Aminoglutethimide / Q000627:therapeutic use; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003613:Danazol / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D013629:Tamoxifen; D000616:Aminoglutethimide; D005047:Etoposide; D003613:Danazol
AMSA/Etoposid (VP 16-213). Eine Phase I/II Studie bei refraktärer akuter myeloischer Leukämie.